Yichen Wang

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1β.

IL-26 Potentiates Type 2 Skin Inflammation in the Presence of IL-1β.

Journal: The Journal of investigative dermatology

Published: July 07, 2023

Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice.

Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice.

Journal: European journal of pharmacology

Published: December 12, 2022

Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.

Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.

Journal: The Journal of investigative dermatology

Published: March 09, 2022

Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea.

Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea.

Journal: JCI insight

Published: May 27, 2021

A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.

A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.

Journal: The Journal of investigative dermatology

Published: October 14, 2020

Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities.

Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities.

Journal: Journal of lipid research

Published: January 20, 2020

Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].

Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].

Journal: Bioorganic & medicinal chemistry letters

Published: December 21, 2019

Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome.

Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome.

Journal: Cell reports

Published: October 29, 2019

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 23, 2019

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

Journal: Bioorganic & medicinal chemistry letters

Published: February 18, 2019

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

Journal: Acta crystallographica. Section F, Structural biology communications

Published: January 14, 2019

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

Journal: Bioorganic & medicinal chemistry letters

Published: December 11, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026